Disease Modelling Services
In vitro retinal disease modelling for retinal therapy. Newcells offers a fast and reliable in vitro safety and efficacy service for the evaluation of novel compounds for retinal therapy using complex human retinal organoid or RPE models developed in house. Both models are iPSC derived allowing gene-edited lines to be engineered using CRISPR/Cas9 for direct comparison between WT and mutant phenotypes after differentiation. Targeted mutations can model retinopathies, more specifically monogenic inherited retinopathies such as retinitis pigmentosa (RP), Stargardt disease, Usher’s syndrome and Leber congenital amaurosis.
Service Outputs
- Phenotypic comparison of WT and gene-edited retinal organoids or RPE cells
- Analysis of key markers by qualitative immunofluorescence
- Assessment of cell type composition of the retinal organoids using imaging techniques
- Evaluation of photoreceptor degeneration
- Loss of RPE barrier function analysis
- Loss of phagocytosis of photoreceptor outer segment in RPE analysis
- Time points comparisons (D60, D120, D150, D210)
Details
- Cell viability assay
- Key markers analysis
- Qualitative immunofluorescence
- Gene expression
- Photoreceptor degeneration
- Phagocytosis of photoreceptor outer segment (RPE)
- Transmission (TEM) and Scanning (SEM) electron microscopy
- Human retinal organoids
- Retinal pigment epithelium (RPE)
- Derived from WT or CRISPR/Cas9 gene edited iPSCs
- Rapid
- 3-6 months
Newcells Retinal Models
Accelerate your lead compound selection by understanding their mode of action in functional retinal tissue
- Recapitulate the architecture and function of the human retina
- Retinal disease modelling with genetic engineering techniques
- Accelerate drug discovery
Customer reviews
No reviews were found for Disease Modelling Services. Be the first to review!